NUST Institutions Library Catalogue

Advanced liver diseases (ALD) continue to pose significant health challenges due to their
high global prevalence and limited currently available curative options, besides liver
transplantation. Liver disease therapeutics include many substances that may have
insufficient effectiveness and severe adverse effects, such as Etoposide, having toxic
nature with low compatibility and solubility in an aqueous solution. Nanoparticle-based
therapeutics emerged as an efficient and safe treatment option to minimize side effects.
Etoposide used for ALD is more toxic with low biocompatibility and solubility in an
aqueous solution which makes it less efficient. The purpose of the study is to use
nanoparticle-based etoposide for the treatment of ALD by improving its biocompatibility
and solubility which makes this target-based therapy less toxic and more effective. Rat
models used in this study were introduced with CCL4 and Urethane co-administration to
develop liver cirrhosis. The thin film hydration method was used to synthesize etoposideencapsulated liposomal nanoparticles. The stability and stealth effect of liposomes were
enhanced by polyethylene glycol (PEG) coating. Etoposides and PEG-coated etoposide
liposomes were administered intravenously, into diseased rats. Results showed that
etoposide and PEG-coated liposomal encapsulation are highly effective as compared to
etoposide alone and blank nanoparticles and hence, be a substantial strategy for the
treatment of ALD through intravenous drug delivery system.